AbbVie 1st-qtr sales and earnings beat analysts' estimates

27 April 2017
abbvie-logo-big

US pharma major AbbVie (NYSE: ABBV) today posted first-quarter 2017 financial results, saying revenue came in at $6.54 billion, up 10% on an operation basis, and beating the consensus analysts’ estimate of $6.48 billion.

Net earnings were $1.71 billion, an increase of 26%. Earnings per share were 41.28, $0.02 better than the analyst estimate of $1.26. Earnings before income tax and expenses rose 17.5% to $2.09 billion. The company’s shares were up 1.34% at $65.04 in pre-market trading and rose a further 3.15% to $67.16 by mid-morning.

Full-year 2017 outlook

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical